Ewa LLC Makes New $68,000 Investment in Kamada Ltd. (NASDAQ:KMDA)

Ewa LLC purchased a new position in Kamada Ltd. (NASDAQ:KMDA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,851 shares of the biotechnology company’s stock, valued at approximately $68,000.

Separately, Y.D. More Investments Ltd acquired a new position in shares of Kamada in the 3rd quarter valued at about $75,000. 20.38% of the stock is owned by institutional investors.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded up $0.13 during mid-day trading on Monday, hitting $5.28. 8,526 shares of the company traded hands, compared to its average volume of 22,523. The firm has a market cap of $303.49 million, a P/E ratio of 34.33 and a beta of 1.04. Kamada Ltd. has a 52-week low of $4.08 and a 52-week high of $6.53. The firm’s 50 day simple moving average is $5.67 and its 200 day simple moving average is $5.47.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.05 by $0.04. The business had revenue of $36.43 million for the quarter, compared to the consensus estimate of $37.71 million. Kamada had a return on equity of 5.66% and a net margin of 5.81%. Equities research analysts expect that Kamada Ltd. will post 0.23 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on KMDA shares. StockNews.com raised Kamada from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Thursday, March 7th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.